C12N 2760/16171
Demonstrated in vivo effect
C12N2760/16171 (Demonstrated in vivo effect) appears on 211 US grants and 309 published applications in this corpus.
Search patents in C12N- Granted patents
- 211
- Published applications
- 309
- Assignees
- 147
- Inventors
- 545
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 1 | 1 |
| 2005 | 1 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 4 | 7 |
| 2010 | 1 | 8 |
| 2011 | 3 | 13 |
| 2012 | 2 | 10 |
| 2013 | 5 | 16 |
| 2014 | 9 | 11 |
| 2015 | 12 | 22 |
| 2016 | 18 | 20 |
| 2017 | 12 | 30 |
| 2018 | 20 | 15 |
| 2019 | 23 | 22 |
| 2020 | 17 | 15 |
| 2021 | 12 | 14 |
| 2022 | 14 | 29 |
| 2023 | 15 | 18 |
| 2024 | 15 | 21 |
| 2025 | 17 | 13 |
| 2026 | 8 | 17 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for prevention and treatment of viral disease25 Aug 2026US 12,714,746 B2Morehouse School of Medicine
- Multivalent nanoparticle-based vaccines23 Jun 2026US 12,661,322 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Recombinant neuraminidase and uses thereof16 Jun 2026US 12,655,408 B2Icahn School of Medicine at Mount Sinai
- Recombinant non-structural protein 1, recombinant influenza virus and immunological composition including the same, and method of treating or preventing disease or condition caused by or associated with influenza virus26 May 2026US 12,636,358 B2National Cheng Kung University
- Modified virus-like particles of CMV21 Apr 2026US 12,605,454 B2Saiba GmbH
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Method for prevention and treatment of viral disease27 Aug 2026US 2026/0248904 A1Morehouse School of Medicine
- Mosaic influenza virus hemagglutinin polypeptides and uses thereof30 Jul 2026US 2026/0216314 A1Icahn School of Medicine at Mount Sinai
- Novel influenza antigens23 Jul 2026US 2026/0207732 A1Glaxosmithkline Biologicals SA
- Immunogenic compositions against influenza11 Jun 2026US 2026/0158128 A1FluGen, Inc.
Most cited
By later US patents
- Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof56US 8,470,310 B2The Trustees of the University of Pennsylvania · 2013
- Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof46US 9,597,363 B2The Trustees of the University of Pennsylvania · 2017
- Noninvasive genetic immunization, expression products therefrom, and uses thereof39US 6,716,823 B1The UAB Research Foundation · 2004
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003